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~ Dobut~mlne-lndu¢~l Changn In Regional 
Myocardlal  Func-llon Aro Cnused by a Mlem~lctt 
Botwtten CMdla© Work and Coronary Flow hl the 
~ ¢ e  of  a Slgntf lcant ComnaP/Ar tery  St=moel= 
O, pavlt($es, P. Ip~lropo~fll, G,'r. Klmt~pBkis, GD, Att~anassopouloa, 
A- IL#.~~~'t~ß~, V- Vas~likoS, E, GlasA~~~l, O,V, Cokkin0B, ~st Cael~l~o/~ 
O~~a~~~~m~, Onas~ Ca~~c S~~~V C~n~;, 4P~=~ G~ece 
~-~t'~.~ t ff: ~ n e  (DOb) IS A Wt(t~ UbCd l~nt t0e p fOdu¢ing l~l!em~ 
(Echo), ~ ' ,  the m~~,t ~ rn~harùsm et reis 
Me~:  ~stmss~nd~;ed  ~ !  myoca«~:t~; t~mn (RMF) w~s 
aSsessed in ~~lal~4~ to (:l~ßllgl~i m ~r~ac work ~ (~~rtary f~w (CF) ~I~l  
20 Ste~~~ CO~O~I w adet~es (StCA) (80 * 14%) wllh a 0014 D0pptee" 
It~~m. ! ~ !  W ~ (~ #g&g.~'~n) was aßmlnt~slered, A~eratTu 
CF ~ (APV, cm/sec)= beart mte-~essum ~0~~ct (RPP) comnary 
perk~~on pmss~m (CPP) iMean Aa P~LVEDP) and WM scom It = normal 
m 4 = ~kme~!  wem ca~tä~ed 
Resut~s~ 
CPP ~ ~ 13 94 ~ 11 OB = 14 t~3 « t2 94 ~ 16 
I~~ tL'~o04 ~ 17,55 1t008 =- 2144 t3~~B4 ~~'  15G75 J: 40~5 ~ 1751:5 ~ 4085 ~ 
APV 1O~t~t 1t~52 1~7 ~?6" 176:76  t73~74 
%J= 6 ~ 18 61 ~ 58 87 ~ 74 91 ~ ~3 
RMF 183 : 001 töt ~ 01~1 161 : 064 21- '01 = 
Concä~~~ At Iow (X~s~ D~b st~ess thete ~s no s@-~ficam change m CF 
wt~~e ~ ~s a s~gl'tl ~mp~~ in ~ At mtermec~ate Do13 do.~e ~e W~ 
~mprovement ~s s ~  as card~ac ~ and CF both rrt~~ease s~,~r'¢anth, 
At peak Dob slres~, WM (leteno«af]on ~ ~ a ~ befween 
the s~gn~fi,::~~m! ~ mcrease m cardrac work and an ~ns~j~f~canl fun'P, er 
mcmase m CF wh~h prm,'es m~K/equate to ~ t e  for the mcre~,ed 
11:15 
[ -~- - - ' ]  P f  es ehre t ion o f  Coronary Blood Row by in Humans 
Esmolol Dur ing Oobutamine 
M. OO~an. M Kern. R. ~~ctt, R. Casteflo. T Donohue. C. Mec~em. J ~t. 
V~Jn. E Dtesster, A. ~tz .  St Louzs Unwet~y ,~'hool of Med~one. USA 
The eff~cacy of beta-bfocker~ dunng ac~lte myocardial infar~o~ ~s weil es- 
tablished ~er .  lhe=r effe~ dunng acutety mduce~ ~scherma on lefl ~en- 
tncutar f ~  and c~~ary  bk:o3 flow =s not descnbed. Therefore. we 
sttl~~~t t~ eff~~~t$ O| in~v~:'1ot[s bet~-b~ocker (Esmo•ol) dun~ O¢(3ut~m~r~ 
(Dob) induced acute ~schemm m 21 paltents using StreSs Ecl~o~ar~o~~raphy 
(DSE) betore and again after Esmolol (titraled to 24 mg/min}. Post-stermbc 
coronary bfood fiow vek3¢ity (CBFV). heart rate (HR). blood pressure (BP), 
at base and peak [:)ob infus~on t~lth and wlthoul Esmolo (E) were compare<l. 
F~ak CBFV %'~ CI~FV HR~BP HR 
Do~utarnm.~ (D;
Posd~~e IPOS) 19«16 33:57 175B2 : 3903 117 ." 18 
Neg'a~tve(Neg) 26 *. 17 72 : 50 1444.4 : 3~~~7 11B : 19 
NS NS NS NS 
Dobutamme &Esrnolol (D-E) 
Posttn~e 1~ ,- 10 30 : 47 13~83 ± 3554 83 .* 1~ 
Negatwo 18 "- 10 36 t 4~ 1|~1| ~ ~1~4 76 ~ 15 
P NS NS 0 05 NS 
P" NS NS 0 00q3 0 001 
P" 00f 001 OOl ooot 
P = ~os ','s ne~j. P" = posD vs posD-E: P'" = negD vs negD*E 
Alter Esmolol, dunng positive DSE, myOCardial demand (BPxHP~) is re- 
duced, CBFV is maintained; while dunng negative DSE. CBFV decreased 
(26 ~ 17 vs 18 ± 10. p < 001 ) wilh decre~se in myocardial oxygen demand. 
Conclusion: Under ischemic sbmulafion. Esmolol favorably altered coro- 
na~t auto-re~J~t~lton presewing CBFV tor any increase in myocardia[ oxygen 
demand. 
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~ Altomlltlon In ColtatOral Flow Dyrmmk:~ Is a 
Oetermlnant of StmSS-lnduced Myocardtal MChemla 
In Humans 
Y Sakata, K Ko(:~ma, A Hiri~y~f1~, Y.-J Um, M K~,  M Hort 0~~~ 
P~~c,e ~~¢.~,t~~, O ~a. an~/Os~~ Un~~r~~, Su~a, Japan 
~ackg~~«~¢l: |t ~s ~itt mcte~~ he~e~ tw,jo~~~t ~sct'~m~ s ~s,~octate~ w~ 
t~ ~'h~nge m c~tat~risl ffow ~ß/nan~~ dunn 9 myocardial ~s  in 
~th co«o~a~ a~ew d~~ and eomea~y ~#ale~ats 
Mett~x!~: K,~/oca~t contrast eehocar~logr~~ohy w~ pe~tom-,e~ by mlect- 
mg t~~,.~e-.a.te~ eo~ra~ m~t~m into t~e ~tght ec,,m~~ ane~/(RCA) t ~  
and imme~ately afte~ fap¢! a~ I~¢mg in 20 pat~ama with ~a i~ '~ 
catty ~nae~eO cor~na~/c~~tera~ to the o¢~tu¢le4 k~t ante~ 
Corona~y =Iftery ~ f~ RCA, Tho p~ak D a c k g ~ ~  
~ ~  (PCt) m me ee~laterat temter~ and ~t~ ~atm to tha! in the 
temtor~ w~,m compared ~ pa~ w~ (n = 0) and w~out (n = lt) 
lactate productmn (LP) in the collatcr~l terntmy durmg rap~ ama~ paei~g. 
R~uf~ l)PCiar~PC!raf~o~torapa~lnOd~not~ffe~betweenpattents 
w~th and w~ou~~ LP (PCL 13.8 ~: 19.1 U vs 10.2 ~: t3.3U, p = 015; PCI raùo; 
070 t 0.71 v~ 067 • 0.~5, p == 0.58, «~We~y) ,  2) However, Do~ PCI 
~nd PCI ratio wem ~~cmased by alnaI pacm 9 mom a~g~n~cantly in paltem~ 
~~h LP than in ~e w~hout (PCI: -67 ± 53% v~ ~~ 15 + 34%, p < 0.05; I~CI 
ratlo: -68 z: 4[% us 6 .2  ± 32%, p < 0.05. re~ve ly ) .  3) ~ wall 
mo~~n al Pa lme,  sever~ of fDe do~or RCA sle~O~s, and other baselme 
crmractensl~c~ em s~n~~az between ~ w~*h and ~ LP 
Conct~~o«, T~se ~afa suggested tf~t pmvocaf~n of my~car~ial m- 
chern~ was c,c;ely assoc~te~ ~ altematmn in col~eral flow (~n~~mcs 
durmg slress, ~ather ff~an fne e=fent of co/~~ferad fiow at rest in pat~~~ts wnh 
a~g~grap~m:a h/ev~'encea coronary colta~rals. 
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~ Coronary Va=o=pasm as a Source of  Farn  Po=nha= 
Results Ouring Dobutamine Echocatt l log~phy 
A Varga. T Fors'ter, E Cseh, L V;uga, M Csanady, E Pfcano', 
A Szent-GycrgyL Unn~t,~~y P,~tedtc~ SchOof. S2~=ged, Hungary: 'CNR, 
ms¢lu~ of Gin.~ca/ Physiology, Ptsa, t~y 
Backgtour~: OoDutamme can mduce coronary tmsoconstnctton r rougtt ab 
pMa-t adrenomceptor st*mulatmn, and arm(:doc~cal cases of ~~l~Jtamme 
induced coronary vasospasm have been reported. The aim o| the study was 
to assess wflether coronaPt vasOspasm (:an be a mgnificant source of false 
pos~l~e resuffs dunng dobufarmrm stress. 
P,~=ttm0~s We con~dered 254 consecul~e paltents who un0erwenl dobu. 
ramme ech¢¢ardTography (up tP -I0 » g/kg.~'nm a~m a/ropme 1 mg ~t needed) 
b~fore coronarv ~=r~~~graphy. and we analyzed the 54 palrent~ (35 men, 19 
wOmen, mein age 49 ~ 10 years) w~h a normal angiogram. 
Resulrs. Du.nng the ang~ograp.hy spontaneous coronary aftery spasm 
oC'cu«ed in 6 ~ents .  ~utamme stTess echo was positive m 6 out of 6 
patte~ts wirb. and onht m 7 out of the 48 paltents wtthout angmgraphicafh/ 
Corooary vasospasm (100% v,s 14%, p < 001). Out of the 6 
patlents ~ posrtn~ dobutamme slrass echo 5 reported chesl pain dunng 
the exan~na0on, hut only 2 had addffional ECG changas In all paltents w~th 
angvograp~Cally documenfed vasosoasm the reg~ons howing dobutamme 
=nduced dySft,~ctto~ wem supphed by the coronary w~th ang~t~~cally 
o'~umer~e~ spasm. 
Condus~n Coronary arte~ spasm can be an in'~ortant source of talse 
pos=twe resuftS o~unng dobutamme stmss echo~ardlogmphy. 
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88~8~-1 j Oral Dofetlltde for Converslon of Patlents Wffh 
Chroni¢ Atrial Fibril lation or  Atrial Flutter to Normal 
Sinus Rhvthm: A Multicenter Study 
S.N. Singh. M.R. 8erk. LG. Yeflen. RG Zoble. D. Abrahamson. C Satler. 
T, Fnednch. Veterans Affatrs Medical Center, Wachington, DC, USA 
Ootet~~i~Je, a class ffl anti-~ntlythmlc agent is a potent setective potassium 
channel bf0cker being devetoped for a brOad fange of tachyarrhylhmt0s 
including atna! fibnllation and atrial flutter (AF/AF 1 ). We examined the efficacy 
and safety ot oral dofetiSde for converting patlenl:s wffh chronic AF/AF1 to 
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stucly, Three hundrecl twenty.flve patlents[277AF/48AF1; 84% male: avemge 
age • 67 yeam; dumtlon of AF/AFI, R wesks-7 months; NYHA: I ,  28%, II 
ù 64%, III - 8%] wem randomlzed to 1 of 4 treatmant gmups: 
Dofetltldo 125 mag, 250 mag, 500 mag, er placebo BID, The numher of 
pstlentl who aehlevnd N.~R allor 3 dlys of oral doslng wem ss follows: 
plsoebo 1/82 (1%), dofetlUde 125 mag 5/74 (6%), dofatlllda 280 m~ 8/79 
(t0,1%), dofetlllda 600 mag 23/71 (32%), Advoma arrests wem batanced 
aeron tmmlment gmups, No tomsdss ner daaths o~urmd, 
Con¢luslon: We oonclude that oratly ~dmlntsfere(:l dofatlllde at 500 me0 
0lD Il effo¢tlvo and safe In convarllng ehmnl0 atrtal flbrlllstlonffluttar fo normel 
slnul dlylhm, 
10:45 
~ IntrlvengUl Vlnlul In Rlolnl Proplfenono Olgoxln 
Onnt Atdld Flbtlllotlon. A PlllOebo-eontmltN, 
Rlmdomllmd 81udy 
L, Btlm~nl, On tJetmtf of R4FIT.3 Inv~fl~tom; $, Flllt~oo Net~ Hospltal, 
~n( / :  Intmv~nouo pmp~fenone (Pmp) h{ls been ehown to eJff~tlv~ly 
metom slnus ~hythm In moent onsal +tilgst flbflll+ltton (AF), whlle tha alfto+lW ot 
Iv dl~o~in (Olg) hu  b~n quolltlonod, Howovor, ~ dlmot ~oml~dllon mono 
thxa dn~lll i~nd plaoebo (Pl~le) le still I~~klng, 
Malfto~: Oßa hundr~ tw~nty lhmo pte wlth AF lasttn9 <7~ hm wem 
mndomlzed 1o silber Iv Pmp (g mg/Kg, 41 p~) or Iv O19 (0,5 mg, 40 ptel) or 
Plao (4~ pte), After 1 hour, non,eonvened Pmp o~ D~ 9 pts wem ewltohed to 
lho oll~r d~~l, whlll non,oonv~rt«] PIke pt~ wem mndoml~ed to nlthm iv 
Pmp er Dt9 and monltomd for a lurthet heer, 
R~uffa: A~r  the first tmatn'~nt, 20/41 (49%) Pmp pts wem onrdlove~~d, 
venlus 12/40 Ot9 pta (32%) and 6/42 Pilz0 ple (14%), The table sparte the 
mlldlve e111¢l~y (RE) of the dnlgs oslculMad by IOglStlo mgmsslon anatysls, 
Am~ng the 47 pt~ mstant to the filet t~tmant who wem 8wlt¢hed to the 
altem•tlve dmg, Olg was effectlva in t/20 pts (5%) nnd Pmp in 12/~7 (48%) 
pla (p < O,OS). tn the 35 w0n-convel1~l Pl8e p~ elloeafed to ~n ~¢tlve dmg, 
slnus rhythm was obtalmKI in 10/19 pts (53%) by Prop and in 1118 pts (5%) 
by Dl9 (p < O.OS). ConsltJeting all the 118 pts who 11~"elved a dn~g as a first 
~tl~l tmalment, ~onvenllon rotes wem 50% (30R0 pl~) wlth Pmp and R5% 
(14/S8 pt~) wlth Olg (p < O,0t, C,I, 95%1,2-3,4), No etgnifi~ant stde efle(:ts 
wem obsonmd In any pts. 
RE C,I, 95% p 
Prop vs Plac 3.41 1,53-?,63 .0.01 
I~g vz PI~ 2E7 0,9e-,~.40 NS 
Prop va 0t 9 1 50 097-2,59 NS 
Conc/usk~: In m,.-'ent onset AF Iv pmpafenone festeres s~nus mylhm 
mom effectlvely than etther plac'flbo r tv dtgoxln, 
11:00 
~ Effi©ll¢y and Safety o1 Intmvonous Flecslnlde 
Compamd to ami  Qulnldlne tor  Convemlon o1 Acute 
Atdld Flbri l latlon (AF) to Slnus Rhythm In Patlents 
P~tlreated Wlth Intravenous Metoprolo l  - The 
FLEQUIN Trlal 
M.O, Hallr~n, A. Pulkklnen, J, Mustonen, M, Puhakka, M. Huftunen, 
S, Paskklnen, L, l~rssanen, M, NIsslnen, J, Melln, T, OIll, Dept, of Medlclne. 
Kz~WO Un~~erstly I'fOS~tal, Kuopto; 4 Central Hospltats, Easfem, Finland 
Ob~ves:  We sfodled the efficacy and safety oi i.v. flecalntdo compamd 
wlth erst qulnldlne for the convemion of saufe AF after Lv. metoprolol was 
glven to Iower ventrlcular ufe, 
~¢k~ound: Eftectlve and safe treatment oi saufe AF is needod in the 
emelgency team. A detay in conversion to slnus rhythm (SR) prolongs the 
hosplfel t~tment and Incmases costs. 
Methoats.' A randomiseck double blind comparison between flecainide (2 
mg/kg wlthtn 30 min.) and qulnldlne (200 mg up to 3 tlmes 2 hr apart) was 
perfon~ed In 163 patlents wlth acufe (<48 hours) AF after metoprolol was 
given openly. 
Resutts: SR was restored within three hours in 45 (54"/0) of the 83 patlents 
In the flecainldo group and in 24 (30%) of the 80 park nts in the qulntdine 
group (p = 0.0018). DC cardlovemion was needed in 23% and lq% of 
patlents (14,S.), and the medien detays to SR ware 0.8 hours and 4.1 hours 
in the fleealnk~e end quintdine gmups, respectlvely (p < 0,001), The medien 
hosplfet sfe:, ~-I p~tients not needing DC ~'~rdloverslon a d pmlonged hospital 
stay (>48 ht) ~^'a~ 6,4 hr in the flecainide group and 9,4 hr in the quinidine 
group, (p = 0,012). Asymptomatic pauses of 3-9.8 seconds wem found in 
ambulstoty ECG recording of 8 patients in the flecalnlde group and of 7 
patients in the quinidine group. Two patients in the flecainido group had a 
shorl lasting circulatory collapse. 
Conclualons: Fle~alnlde actod mom rapldly In mstodn9 8R than qulnldlne. 
Both druga wem safe for the tmalment of outpatient~ in the emergeney 
room, I,v, metopmtol was a safe pmtmatment for petionts tmated wlth etther 
flecalnlde or qulntdlne, 
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~ A©ut~ Atrlol Flbrl l lat lon' Hlgh,l~N IV Amlodorone 
Fu l l i to tu  Convemlon to  Nofmol  81nus Rhylhm. 
When is it Ne~ss l ry?  
G, Cottor, E, Coltet.Melzkor, E. Kalulki, A, 0tat, Y, M01~kovltz, I Ulk~ky, 
M, Komn, R. Zt|ldensfeln, A, Gollk, Amf.P~n~#ft Me(J~al O#nt~, 
tarne/ 
The rate of epontsneoul ¢onwrelon of ~ Iztfial fibd!lat!on (A« AF) to 
normal sinus dlythm (NBR) le high and not affo¢tod by Iow ¢lole lmto¢lemee 
(Am,) trimtnl~nt, We lvaloltt¢l high.deN Am, in 1ha tfelftllent et A~D AF. 
Metho~: Etghty pallanta (ptl,) wlth parox~mat AF, ~ for A~~ AF 
(,~48 h) wem random~ed to m¢elve for 24 t~um: (1) Group A, (n = 40); 
Pl~l~bo (R) Group 6, (n ~ 40): ~H1tlnuou8 IV Am, 120 mg/h~f (tl~M 3 9), 
Group A pta, not oonvolttn9 to NSR wtfhin 24 bi' wem ommled ~ to Am 
Ihempy, All p~, meeWed OIgoxln, 
Resut~; Basellna pulea was 1~7 ± 19 beafi/min, and ± al beatMmm, in 
gmups A and B, in group A, 2? pilz, (67%) (xmveltod 1o NSR w. 3B (90%) in 
group B (p .  0,029), ~nty. fhte of 27 (93%) pls, ¢~~,e~nQ SlXmtaneoulW 
(in group A) have ¢onverted within t 2 hmlm, Eleven pts, (85%) in t~ B not 
+co~~!11111g on plaeetlo have c~nvetted after being ~ O~ef to 
Am, t~tment, Flnally, 0 pt~, (in both gmup~) dtd not colwe~t on 
Am,, 3 ~ve~KI  a~tot ele¢td~l ~rdlovefetoß, ~ all 6 wem in ch~ AF 
after 1 month, In p~, still In AF ~fter 8 houm et tmatme~, the putse fete 
deemased to 114 :E 20 txlafe/m~n, ingroup A v*. 83 ± 15 beets/min, tn graue 
B (p = 0.0014). No advefse event~ mquldng tmalment O¢¢UnIKI in (Imu~ B 
pts. 
t 
Cot¢lusk~n: IV high-dose Am. tmatment (120 mg/ht) is safe and lacilitates 
convemlon O1 Ac AF to NSR. Spontaneous conve~sion commonty occurs 
wlthln 12 hours, themtom, high-dose Am. may be resen~ed for pts. mquiring 
rate control, tang form Am. tmatment er not convefling within 12 heus. Pts 
resistant 1o high-dose Am. am at high risk of developing chronic AF. 
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~ ~ 7  Class III Drugs for  Suppress ion  of  Recurrent 
Symptomatic Atrktl F ibdl lat ion 
G.E. Kochiadakts, N.E. Igoumentdis, M.E. Marketou, M.C. Solomou, 
E.M. Kanoupakis, P.E. Vardas. C.aro'/ofogy Dept., Hersklion University 
Hospital. Cmte. Gmece 
Background: In this comparative trist, we examined the efficacy and safety of 
amtodamne and sotatol in maimaining nom~t sinus rhythm in patients (pts) 
with retractonj atdal fibfitlatton. 
Methods: Seventy consecutive pts (39 men, mean age 63.1 ± 9 years) 
,ver: randomized into two clinicatly similar groups: 35 received amiodamne 
and 33 sutalot. Pts with ejection fractton <40% er clinlcatly significant heal~ 
disease wem excluded, The amiodamne dosage began with 800 to 1600 
mg/day for 7 to 14 doys oralty and was then fepered over 7 to 12 days, gen- 
erally to 200 mgtday. The sotatol dosage was 160-360 mgtday, as *.olo=t~d. 
Fotlow up clinlcai evatuations wem conducted at 2 month intewals tor the first 
6 months and at 3 month Intetvals thereafter. The propodion of pts mmaining 
in slnus rhy~hl~~ was calculafed for the two groups using the Kaplan-Mefer 
method. 
Results: Ten o1 the 35 p~ on amiodamne developed atrial fibrillation 
during the 12-month obsewation period, compared to 21 of the sotalol group 
(p = 0.008). Progmssion to atriat fibrillation was faster in the sotaloi pts 
(p = 0,012): after 6 months, 77.4% of amiodamne pts remained in normal 
sinus rhythm compared to 54.3% of the sotalol pts, whife at 12 months the 
respective percentages wem 71% and 40%. Sex, age, left atdat size and 
atrial fibrillation type had no significant effect. 
